首页> 外文期刊>American Journal of Surgical Pathology >Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers
【24h】

Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers

机译:单纯顶泌癌代表三阴性乳腺癌的临床病理学上不同的雄激素受体阳性亚型。

获取原文
获取原文并翻译 | 示例
           

摘要

Apocrine carcinomas comprise approximate to 1% of all breast cancers and are characterized by large cells bearing abundant eosinophilic granular cytoplasm, round nuclei, and prominent nucleoli. They are typically estrogen receptor/progesterone receptor/HER2 negative, making them unresponsive to typical hormonal or HER2-based chemotherapy. However, this subtype of triple-negative breast cancers expresses androgen receptor (AR), a feature not shared by most nonapocrine triple-negative cancers (NA-TNCs). AR therefore represents a potential diagnostic tool and therapeutic target for apocrine breast carcinoma. All pure apocrine carcinomas diagnosed during a 10-year period were reviewed, and clinicopathologic characteristics were compared with a control group of 26 NA-TNC cases. Twenty apocrine carcinomas were identified (approximate to 0.8% of all breast cancers). The mean age at diagnosis was 69.3 years for apocrine carcinomas and 56.7 years for NA-TNC. All apocrine carcinomas and no NA-TNC were AR positive. The proportions of apocrine carcinoma grades varied, with G1 being seen in 15% of patients, G2 in 55%, and G3 in 30%. In contrast, 100% of NA-TNC cases were G3. The majority of apocrine carcinomas presented at low T stage (T1: 70%; T2: 20%; T3: 10%; T4: 0%), whereas NA-TNC cases more often presented at T2 or higher (T1: 46.2%; T2: 30.8%; T3: 11.5%; T4: 11.5%). Thirty percent of apocrine carcinomas and 30.8% of NA-TNCs had nodal metastases at presentation. Apocrine carcinomas had a favorable clinical prognosis, with 80% of patients showing no evidence of disease-related morbidity or mortality (mean follow-up: 45.2 mo). Pure apocrine carcinomas represent a clinicopathologically distinct subgroup of triple-negative breast cancer characterized by AR positivity. When compared with NA-TNC, apocrine carcinomas more often present in older women with lower grade and T stage, a group in which a more conservative treatment regimen is often desired.
机译:泌乳腺癌约占所有乳腺癌的1%,其特征是带有大量嗜酸性粒细胞,圆形核和突出核仁的大细胞。它们通常是雌激素受体/孕激素受体/ HER2阴性的,因此对典型的激素或基于HER2的化学疗法无反应。但是,这种三阴性乳腺癌亚型表达雄激素受体(AR),这是大多数非绝经三阴性乳腺癌(NA-TNC)所不具备的特征。因此,AR代表了顶泌性乳腺癌的潜在诊断工具和治疗目标。回顾了在10年内诊断出的所有纯顶分泌癌,并将其临床病理特征与26例NA-TNC病例的对照组进行了比较。鉴定出二十种顶细胞癌(约占所有乳腺癌的0.8%)。顶癌的诊断平均年龄为69.3岁,NA-TNC的平均诊断年龄为56.7岁。所有的内分泌癌且无NA-TNC均为AR阳性。顶泌癌分级的比例各不相同,在15%的患者中观察到G1,在55%的患者中观察到G2,在30%的患者中观察到G3。相反,NA-TNC病例中100%为G3。大多数顶泌癌在低T期出现(T1:70%; T2:20%; T3:10%; T4:0%),而NA-TNC病例更常出现在T2或更高的阶段(T1:46.2%; T1:46.2%)。 T2:30.8%; T3:11.5%; T4:11.5%)。提出时有30%的顶分泌癌和30.8%的NA-TNC有淋巴结转移。顶头癌的临床预后良好,80%的患者未显示出与疾病相关的发病率或死亡率的证据(平均随访:45.2 mo)。纯载脂腺癌代表AR阳性为特征的三阴性乳腺癌的临床病理学上独特的亚组。与NA-TNC相比,顶位癌多见于年级和T期较低的老年女性,这是一个通常需要更保守治疗方案的人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号